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ABSTRACT
Purpose: To compare long-term disease-free survival (DFS) between patients receiving 
tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant 
chemotherapy (AC) for gastric cancer (GC).
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Materials and Methods: This retrospective multicenter observational study enrolled 983 
patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX 
for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. 
We conducted propensity score matching to reduce selection bias. Long-term oncologic 
outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively.
Results: The median and longest follow-up period were 59.0 and 87.6 months, respectively. 
DFS rate did not differ between patients who received S-1 and CAPOX for pathologic stage 
II (P=0.677) and stage III (P=0.899) GC. Moreover, hazard ratio (HR) for recurrence did not 
differ significantly between S-1 and CAPOX (reference) in stage II (HR, 1.846; 95% confidence 
interval [CI], 0.693–4.919; P=0.220) and stage III (HR, 0.942; 95% CI, 0.664–1.337; P=0.738) 
GC. After adjustment for significance in multivariate analysis, pT (4 vs. 1) (HR, 11.667; 95% 
CI, 1.595–85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502–5.174; P=0.001), 
and completion of planned chemotherapy (HR, 2.213; 95% CI, 1.618–3.028; P<0.001) were 
determined as independent prognostic factors for DFS.
Conclusions: S-1 and CAPOX AC regimens did not show significant difference in over-5yr 
DFS after curative gastrectomy in patients with stage II or III GC. The pT, pN stage, and 
completion of planned chemotherapy were prognostic factors for GC recurrence.
Keywords: Gastric cancer; Adjuvant chemotherapy; Disease-free survival
INTRODUCTION
Among various agents for adjuvant chemotherapy (AC) after curative radical gastrectomy 
in patients with stage II and III gastric cancer (GC), tegafur/gimeracil/oteracil (S-1) and 
capecitabine plus oxaliplatin (CAPOX) predominate owing to their remarkable oncologic 
outcomes in 2 multicenter randomized controlled trials (RCTs) proving the efficacy of ACs 
[1,2]. Most physicians or surgical oncologists, especially in Asia, follow similar strategies to 
select AC regimen for GC; in general, the selection is based on the clinicopathologic status of 
a patient. Although the efficacies of S-1 and CAPOX regimens could not be compared directly 
by the 2 previous RCTs, a subgroup analysis of these trials proposed the indications of AC 
regimens. The CAPOX regimen tended to be administered to patients with relatively higher 
stages of GC, whereas S-1 monotherapy was administered to less advanced cases. These 
strategies come from the assumption that CAPOX, a doublet regimen, might be superior over 
S-1 monotherapy in terms of oncologic outcomes.
However, these strategies are not based on reliable studies that directly compare both 
regimens. This issue has remained controversial because the therapeutic effects of the 2 
AC regimens have not been verified by a high-quality evidence extracted from multicenter 
RCTs involving both regimens. In addition, we have no scientific basis to determine 
whether either of the 2 regimens is more effective than the other in terms of long-term 
oncologic outcomes. This issue remains unresolved owing to difficulties in performing 
prospective comparative trials due to commercial and other challenges.
For these reasons, the Surgical Oncology Forum study group launched a multicenter 
retrospective study to compare disease-free survival (DFS) rates at 3 years after surgery 
between patients receiving S-1 monotherapy and those receiving CAPOX doublet 
chemotherapy [3]. The results showed that in patients with relatively higher-stage disease, 
CAPOX was associated with higher DFS than S-1 monotherapy. Although CAPOX regimen 
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may be superior to S-1 monotherapy in terms of 3-year DFS rates in patients with high-stage 
disease, there is still no evidence that CAPOX is superior to S-1 monotherapy in terms of 
outcomes after long-term follow-up in these patients. The results of the previous studies 
investigated the relatively short-term oncologic outcomes rather than the long-term 
efficacy of these 2 AC regimens.
Therefore, the present propensity score-matched multicenter cohort study compared the 
long-term oncologic results over 5 years (over-5yr DFS) after curative resection between 
patients who received AC with S-1 or CAPOX. To the best of our knowledge, this was the first 
multicenter cohort study to evaluate the long-term recurrence outcomes (over-5yr DFS) of 
2 AC regimens in patients with GC after curative gastrectomy.
MATERIALS AND METHODS
Patients
This study included data from 983 patients who underwent curative resection and received 
AC for GC between January 2012 and December 2013 at 27 hospitals in the Republic of Korea. 
The enrolled patients underwent R0 resection by radical gastrectomy with D2 or more lymph 
node dissection according to guidelines [4,5].
Eligible patients 1) were 20 years of age or older; 2) had histologically proven stage II or III 
GC after radical gastrectomy based on the 8th edition of American Joint Committee on 
Cancer (AJCC) cancer staging system; 3) had received S-1 monotherapy or CAPOX regimen 
as an AC within 8 weeks after surgery; 4) had not received preoperative chemotherapy, 
radiotherapy, or immunotherapy; 5) did not have synchronous or metachronous cancer; 
6) did not have distant metastasis; and 7) did not have tumor cells according to peritoneal 
washing cytologic examination [6].
Study design and data collection
We reviewed the clinical status data and medical records of all participating institutions 
in May 2019. The primary endpoint was over-5yr DFS after curative gastrectomy. DFS was 
defined as the time elapsed from the operation date to the recurrence date or the time of 
the last follow-up. The study protocol was approved by the Institutional Review Board of the 
Institute of Radiological and Medical Sciences, Busan, Republic of Korea (No. D-1902-031-
002), which waived the requirement for written informed consent from the patients owing to 
the retrospective study design.
AC regimens
The AC treatments were initiated within 4–8 weeks after curative resection. The 
chemotherapeutic regimens were administered as described by the ACTS-GC and the 
CLASSIC trial [1,2]. Patients in the S-1 group received the treatment at a dose of 40, 50, or 60 
mg twice daily. The dose was determined based on the body surface area of each individual 
patient. Each S-1 cycle included drug administration for 4 weeks, followed by 2 weeks of rest; 
the 6-week cycle was repeated for a total of 8 cycles. Patients in the CAPOX group received 
3-week cycles of oral capecitabine (1,000 mg/m2 twice daily on days 1–14 of each cycle) plus 
intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for a total of 8 cycles. Reductions 
of doses, modifications of schedules, or interruptions of AC were conducted based on a 
clinician's decision considering the events that occurred during AC.
154https://jgc-online.org https://doi.org/10.5230/jgc.2020.20.e13
Adjuvant Chemotherapy for Gastric Cancer
Follow-up
The patients underwent follow-up examinations including abdominal computed tomography 
(CT) scan and/or endoscopy to detect GC recurrence. After AC completion, follow-up 
medical consultations, history-taking, physical examinations, and clinical evaluations were 
recommended every 3–4 months for 2 years and then every half-year for the subsequent 2 
years. After approximately 5 years following surgery, assessments were performed annually 
or once every 2 years. The follow-up evaluations included measurement of gastrointestinal 
tumor markers, simple chest X-ray, abdominal and pelvic enhanced CT scan (AP-CT), and 
upper gastrointestinal endoscopy. Abdominal ultrasonography, chest CT scan, abdominal 
magnetic resonance imaging, positron emission tomography scan, and bone scan were 
additionally performed when AP-CT revealed equivocal abnormalities.
Statistical analysis
Propensity score matching (PSM) based on binary logistic regression was used to minimize 
selection bias caused by imbalanced variables in the historical cohort study (Fig. 1). The 
propensity score model considered clinicopathological characteristics including patients' 
age, sex, American Society of Anesthesiologists (ASA) score, extent of gastrectomy, operation 
method, T stage, N stage, stage according to the 8th AJCC staging system, retrieved lymph 
nodes, tumor size and differentiation, Lauren's classification, and lymphatic and vascular 
invasion. We performed 1:3 matching between the S-1 and CAPOX groups using the nearest-
neighbor matching method without replacement.
IBM SPSS Statistics for Windows, version 19.0 (IBM Corp., Armonk, NY, USA) was used for 
statistical analyses. The chi-square test was used to compare baseline characteristics between 
the 2 groups. The Kaplan–Meier method was used to estimate cumulative DFS with 95% 
confidence intervals (CIs). Breslow or 2-sided log-rank test was used to compare DFS rate 
between the treatment groups. Significant factors in the univariate analysis were included in 
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983 total patients
584 total patients
215 patients 768 patients
339 patients60 patients
155 patients 429 patients
Age, sex, BMI, ASA score, extent of
gastric resection, OP method, T stage,
N stage, AJCC 8th stage, retrieved
lymph nodes, tumor size, differentiation,
Lauren classification, lymphatic invasion,
vascular invasion matched 
by PSM
CAPOX S-1
Fig. 1. Flowchart of PSM. 
CAPOX = capecitabine and oxaliplatin; S-1 = tegafur/gimeracil/oteracil; BMI = body mass index; ASA = American 
Society of Anesthesiologists; OP = operation; AJCC = American Joint Committee on Cancer; PSM = propensity 
score matching.
the multivariate analysis, and the hazard ratios (HRs) for recurrence in the S-1 group, with 
the CAPOX group as a reference, were analyzed using the Cox proportional hazards model. 
P-values less than 0.05 were considered statistically significant.
RESULTS
Patient baseline characteristics
The median and longest follow-up periods were determined to be 59.2 and 87.6 months, 
respectively, before PSM and 59.0 and 87.6 months, respectively, after PSM until the cutoff 
date of April 31, 2019. Table 1 presents the baseline characteristics of patients in the S-1 and 
CAPOX groups. Before PSM (n=983), some clinicopathologic variables differed significantly 
between the 2 groups. Patients in the S-1 group were older (P<0.001); more commonly 
underwent a minimally invasive approach (P<0.001); had less advanced pathologic T, N, 
and AJCC 8th stages (P=0.016, P<0.001, P<0.001); had smaller tumor size (P<0.001); more 
commonly had intestinal-type Lauren classification (P=0.007); less often had lymphatic or 
vascular invasion (P=0.007, P=0.002); and less often completed the planned chemotherapy 
(P=0.027) compared with those in the CAPOX group. After PSM (n=584, Fig. 1), to reduce the 
bias caused by the historical nature of the cohort study, no significant differences in baseline 
characteristics were observed between the S-1 and CAPOX groups.
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Table 1. Baseline characteristics of patients in S-1 and CAPOX groups
Variables Before PSM (n=983) After PSM (n=584)
S-1 (n=768) CAPOX (n=215) P-value Standardized 
difference
S-1 (n=429) CAPOX (n=155) P-value Standardized 
difference
Age (yr) <0.001* 0.343 0.907 0.011
<60 313 (40.76) 124 (57.67) 208 (48.48) 76 (49.03)
≥60 455 (59.24) 91 (42.33) 221 (51.52) 79 (50.97)
Sex 0.091 0.133 0.237 0.112
Male 518 (67.45) 158 (73.49) 285 (66.43) 111 (71.61)
Female 250 (32.55) 57 (26.51) 144 (33.57) 44 (28.39)
BMI (kg/m2) 0.982 0.002 0.394 0.081
≤23 371 (48.5) 103 (48.58) 211 (49.41) 69 (45.39)
>23 394 (51.5) 109 (51.42) 216 (50.59) 83 (54.61)
ASA score 0.440 0.137 0.499 0.152
1 267 (34.86) 86 (40) 168 (39.25) 60 (38.71)
2 407 (53.13) 105 (48.84) 216 (50.47) 74 (47.74)
3 89 (11.62) 24 (11.16) 42 (9.81) 21 (13.55)
4 3 (0.39) 0 (0) 2 (0.47) 0 (0)
Extent of gastric resection 0.946 0.005 0.530 0.059
Subtotal gastrectomy 502 (65.36) 140 (65.12) 273 (63.64) 103 (66.45)
Total gastrectomy 266 (34.64) 75 (34.88) 156 (36.36) 52 (33.55)
Operation approach method <0.001* 0.305 0.530 0.018
Open 605 (78.78) 193 (89.77) 273 (63.64) 103 (66.45)
Laparoscopy or robot 163 (21.22) 22 (10.23) 156 (36.36) 52 (33.55)
pT stage 0.016* 0.254 0.978 0.042
T1 42 (5.47) 6 (2.79) 18 (4.2) 6 (3.87)
T2 120 (15.63) 24 (11.16) 61 (14.22) 23 (14.84)
T3 370 (48.18) 97 (45.12) 185 (43.12) 69 (44.52)
T4 236 (30.73) 88 (40.93) 165 (38.46) 57 (36.77)
pN stage <0.001* 0.661 0.811 0.093
N0 186 (24.22) 17 (7.91) 57 (13.29) 17 (10.97)
N1 184 (23.96) 25 (11.63) 64 (14.92) 25 (16.13)
N2 172 (22.4) 60 (27.91) 113 (26.34) 45 (29.03)
N3 226 (29.43) 113 (52.56) 195 (45.45) 68 (43.87)
(continued to the next page)
DFS and HRs for recurrence after PSM
After PSM, no differences in DFS rate for pathologic stage II (P=0.677) and III (P=0.899) GC 
were observed between the S-1 and CAPOX groups (Fig. 2). In patients with stage II GC, the 
DFS rates were 85.4% (95% CI, 82.3%–88.5%) in the S-1 group and 89.3% (95% CI, 82.6%–
96.0%) in the CAPOX group. In patients with stage III GC, the DFS rates were 56.0% (95% 
CI, 53.2%–58.8%) in the S-1 group and 56.2% (95% CI, 50.5%–61.9%) in the CAPOX group 
(Table 2). Subgroup analysis of stage III GC did not reveal significant differences in DFS rate 
for stage IIIA (P=0.784), IIIB (P=0.834), and IIIC (P=0.435) GC between the 2 groups.
No significant differences in recurrence according to the HR of S-1 compared with that of 
CAPOX as a reference for stage II (HR, 1.846; 95% CI, 0.693–4.919; P=0.220) and stage III 
(HR, 0.942; 95% CI, 0.664–1.337; P=0.738) GC were observed between groups (Table 3). 
Subgroup analysis of patients with stage III GC showed HRs of S-1 for recurrence of 0.873 
(95% CI, 0.466–1.635; P=0.671) for stage IIIA, 1.220 (95% CI, 0.571–2.610; P=0.608) for 
stage IIIB, and 0.813 (95% CI, 0.482–1.371; P=0.437) for stage IIIC. Fig. 3 shows forest plots 
from subgroup analysis of DFS for the 2 groups. The subgroup analysis did not reveal any 
significant differences in recurrence between the S-1 and CAPOX groups.
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Variables Before PSM (n=983) After PSM (n=584)
S-1 (n=768) CAPOX (n=215) P-value Standardized 
difference
S-1 (n=429) CAPOX (n=155) P-value Standardized 
difference
AJCC 8th stage <0.001* 0.666 0.807 0.023
Stage II 415 (54.04) 50 (23.26) 143 (33.33) 50 (32.26)
Stage III 353 (45.96) 165 (76.74) 286 (66.67) 105 (67.74)
Retrieved lymph nodes 0.229 −0.059 0.380 −0.101
≤45 439 (57.16) 113 (52.56) 239 (55.71) 80 (51.61)
>45 329 (42.84) 102 (47.44) 190 (44.29) 75 (48.39)
Tumor size (cm) <0.001* 0.260 0.384 0.082
≤5 430 (56.14) 93 (43.26) 214 (49.88) 71 (45.81)
>5 336 (43.86) 122 (56.74) 215 (50.12) 84 (54.19)
Differentiation 0.341 0.109 0.818 0.059
W or M 263 (34.24) 67 (31.16) 124 (28.9) 49 (31.61)
P or S 463 (60.29) 131 (60.93) 276 (64.34) 96 (61.94)
Others 42 (5.47) 17 (7.91) 29 (6.76) 10 (6.45)
Lauren classification 0.007* 0.276 0.076 0.251
Intestinal 284 (40.34) 62 (34.44) 142 (35.86) 46 (35.94)
Diffuse 335 (47.59) 107 (59.44) 205 (51.77) 75 (58.59)
Mixed 85 (12.07) 11 (6.11) 49 (12.37) 7 (5.47)
Lymphatic invasion 0.007* 0.220 0.781 0.027
No 263 (36.23) 54 (26.09) 113 (28.32) 44 (29.53)
Yes 463 (63.77) 153 (73.91) 286 (71.68) 105 (70.47)
Vascular invasion 0.002* 0.236 0.511 0.063
No 507 (69.26) 120 (57.97) 267 (66.09) 94 (63.09)
Yes 225 (30.74) 87 (42.03) 137 (33.91) 55 (36.91)
Completion of planned 
chemotherapy
0.027* 0.174 0.908 0.011
Yes 503 (65.49) 158 (73.49) 294 (68.53) 107 (69.03)
No 265 (34.51) 57 (26.51) 135 (31.47) 48 (30.97)
Values are presented as number (%).
PSM = propensity score matching; S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin; BMI = body mass index; ASA = American society 
of anesthesiologist; AJCC 8th = 8th edition of American Joint Committee on Cancer; W = well-differentiated; M = moderately-differentiated; P = poorly-
differentiated; S = signet ring cell carcinoma.
*Statistically significant with P<0.05.
Table 1. (Continued) Baseline characteristics of patients in S-1 and CAPOX groups
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Fig. 2. DFS of patients with stage II and III gastric cancer according to adjuvant chemotherapy regimen; (A) stage II, (B) stage IIA, (C) stage IIB, (D) stage III, (E) 
stage IIIA, (F) stage IIIB, and (G) stage IIIC. 
CAPOX = capecitabine and oxaliplatin; S-1 = tegafur/gimeracil/oteracil; DFS = disease-free survival. (continued to the next page)
Sites of recurrence after AC
Table 4 lists the major sites of GC recurrence after AC. The total incidences of recurrence 
were similar between the S-1 (32.9%) and CAPOX (31.6%) groups. Among the major sites of 
recurrence, there were no differences between the peritoneum (HR, 1.040; 95% CI, 0.633–
1.708; P=0.878), hematogenous sites (HR, 0.813; 95% CI, 0.398–1.659; P=0.568), lymph 
nodes (HR, 1.442; 95% CI, 0.710–2.928; P=0.311), and locoregional sites (HR, 1.471; 95% CI, 
0.489–4.425; P=0.492) between groups.
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Fig. 2. (Continued) DFS of patients with stage II and III gastric cancer according to adjuvant chemotherapy regimen; (A) stage II, (B) stage IIA, (C) stage IIB, (D) 
stage III, (E) stage IIIA, (F) stage IIIB, and (G) stage IIIC. 
CAPOX = capecitabine and oxaliplatin; S-1 = tegafur/gimeracil/oteracil; DFS = disease-free survival.
Table 2. Disease free survival rates of S-1 and CAPOX groups according to stages (AJCC 8th) using log-rank test
Stages S-1 (n=429) CAPOX (n=155) P-value
All 66.1 (64.3–67.9) 66.5 (62.5–70.5) 0.961
Stage II
All of stage II 85.4 (82.3–88.5) 89.3 (82.6–96.0) 0.677
Stage IIA 92.1 (87.4–96.8) 92.3 (77.5–107.1) 0.575
Stage IIB 79.6 (74.3–84.9) 87.9 (78.8–97.0) 0.265
Stage III
All of stage III 56.0 (53.2–58.8) 56.2 (50.5–61.9) 0.899
Stage IIIA 72.1 (67.4–76.8) 62.2 (51.9–72.5) 0.784
Stage IIIB 52.5 (45.7–59.3) 74.5 (63.5–85.5) 0.834
Stage IIIC 38.9 (30.9–46.9) 26.0 (6.5–45.5) 0.435
Values are presented as disease free survival rates (95% confidence interval).
S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin; AJCC 8th = 8th edition of American Joint 
Committee on Cancer.
Table 3. HR of S-1 compared with CAPOX as reference for recurrence of gastric cancer
Stages HR 95% CI P-value
All 1.008 0.728–1.395 0.963
Stage II 1.846 0.693–4.919 0.220
Stage IIA 1.727 0.202–14.787 0.618
Stage IIB 2.140 0.710–6.450 0.176
Stage III 0.942 0.664–1.337 0.738
Stage IIIA 0.873 0.466–1.635 0.671
Stage IIIB 1.220 0.571–2.610 0.608
Stage IIIC 0.813 0.482–1.371 0.437
S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin; HR = hazard ratio; CI = confidence interval.
Risk factors for recurrence
In both uni- and multivariate analysis, we entered pT and pN stages instead of the AJCC 8th 
stage. Univariate analysis of risk factors revealed that patient age, ASA score, extent of gastric 
resection, operation approach method, pT and pN stages, tumor size, lymphatic and vascular 
invasions, and completion of planned chemotherapy were significant predictors related 
to DFS. After adjustment for meaningful factors in multivariate analysis, pT (4 vs. 1) (HR, 
11.667; 95% CI, 1.595–85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502–5.174; 
P=0.001), and completion of planned chemotherapy (HR, 2.213; 95% CI, 1.618–3.028; 
P<0.001) were revealed as independent prognostic factors for DFS (Table 5).
160https://jgc-online.org https://doi.org/10.5230/jgc.2020.20.e13
Adjuvant Chemotherapy for Gastric Cancer
Variables Total No. 
of patients
HR 95% CI P-value
Sex
Male 396 1.153 0.784–1.695 0.469
Female 188 0.750 0.408–1.378 0.355
Age
<60 284 0.971 0.595–1.584 0.906
≥60 300 1.011 0.654–1.564 0.959
ASA score
1 228 0.757 0.449–1.279 0.299
2 290 1.414 0.855–2.337 0.177
3 63 0.898 0.407–1.982 0.791
Extent of gastric resection
Subtotal gastrectomy 376 0.942 0.618–1.438 0.783
Total gastrectomy 208 1.084 0.649–1.810 0.759
pT stage
T2 84 1.302 0.424–3.994 0.644
T3 254 1.163 0.664–2.039 0.597
T4 222 0.875 0.570–1.344 0.543
pN stage
N0 74 0.648 0.203–2.070 0.464
N1 89 0.978 0.311–3.074 0.969
N2 158 0.732 0.366–1.461 0.376
N3 263 1.230 0.811–1.864 0.329
AJCC 8th stage
Stage II 193 1.050 0.420–2.623 0.916
Stage III 391 1.041 0.735–1.475 0.820
Tumor size (cm)
≤5 285 1.362 0.759–2.443 0.300
>5 299 0.890 0.599–1.322 0.564
S-1 betterCAPOX better
10.1 10
Fig. 3. Forest plot for subgroup analysis of disease-free survivals in S-1 and CAPOX groups. 
CAPOX = capecitabine and oxaliplatin; S-1 = tegafur/gimeracil/oteracil; HR = hazard ratio; CI = confidence interval; ASA = American Society of Anesthesiologist; 
AJCC 8th, 8th edition of American Joint Committee on Cancer.
Table 4. Major sites of recurrence after adjuvant chemotherapy for gastric cancers
Sites* S-1 CAPOX HR 95% CI P-value
Peritoneum 51 (11.8) 23 (14.8) 1.040 0.633–1.708 0.878
Hematogenous 34 (7.9) 11 (7.1) 0.813 0.398–1.659 0.568
Lymph nodes 45 (10.5) 10 (6.5) 1.442 0.710–2.928 0.311
Locoregional 11 (2.6) 5 (3.2) 1.471 0.489–4.425 0.492
Total No. of recurrences 141 (32.9) 49 (31.6) - - -
Values are presented as number (%).
S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin; HR = hazard ratio; CI = confidence interval.
*Some patients had recurrence more than one site at first relapse.
DISCUSSION
We compared the long-term efficacy of S-1 and CAPOX AC regimens for stage II or III GC 
based on PSM analysis from a multicenter historical cohort study over 5 years after surgery. 
We did not identify any significant difference in over-5yr DFS between the 2 regimens. We 
also observed no significant differences between the 2 regimens in subgroup analysis. The 
pathologic stage and completion of planned chemotherapy were shown as independent 
prognostic factors for DFS.
Previous prominent prospective studies on AC for GCs, the ACTS-GC [1] and CLASSIC 
[2,7] trials, showed the efficacy of S-1 and CAPOX regimens compared with that of no 
chemotherapy. However, they did not directly compare the efficacies of both regimens. 
Therefore, the difference in efficacy between the 2 regimens remained unknown. A recent 
retrospective multicenter study showed that the CAPOX AC regimen was more effective 
than S-1 in patients with stage IIIB or IIIC GC based on 3-year DFS [3]. Another retrospective 
single-center study showed that CAPOX tended to be more effective than S-1 in patients 
with stage IIIC GC after D2 gastrectomy, although the adjuvant CAPOX and S-1 regimens 
did not show any significant difference in patients with stage III GC [8]. Consequently, the 
single-center study concluded that pathologic N stage and cycle completion as planned were 
meaningful prognostic factors for recurrence, comparable to the results of the multivariate 
analysis in the present study.
We did not find any differences in survival between the 2 AC regimens for GC. However, 
previous retrospective studies reported that CAPOX chemotherapy may be superior to S-1 
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Table 5. Univariate and multivariate analysis of risk factors for disease-free survival
Variable Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age (≥60) 1.433 (1.075–1.909) 0.014* 1.014 (0.736–1.396) 0.933
Sex (male) 1.201 (0.877–1.643) 0.253 - -
BMI (>23) 1.014 (0.761–1.35) 0.927 - -
ASA score (2 vs. 1) 1.207 (0.884–1.649) 0.237 - -
ASA score (3 vs. 1) 1.840 (1.17–2.896) 0.008* - -
ASA score (4 vs. 1) 2.577 (0.357–18.594) 0.348 - -
Extent of gastric resection (total) 1.538 (1.155–2.049) 0.003* 1.151 (0.835–1.585) 0.391
Operation approach method (open) 1.647 (1.025–2.647) 0.039* 1.132 (0.670–1.914) 0.643
pT stage (2 vs. 1) 5.133 (0.683–38.573) 0.112 5.260 (0.688–40.19) 0.110
pT stage (3 vs. 1) 7.555 (1.049–54.414) 0.045* 7.043 (0.959–51.719) 0.055
pT stage (4 vs. 1) 15.243 (2.127–109.253) 0.007* 11.667 (1.595–85.351) 0.016*
pN stage (1 vs. 0) 0.797 (0.385–1.651) 0.541 0.942 (0.428–2.074) 0.881
pN stage (2 vs. 0) 1.180 (0.638–2.183) 0.598 1.204 (0.613–2.364) 0.590
pN stage (3 vs. 0) 3.072 (1.766–5.341) <0.001* 2.788 (1.502–5.174) 0.001*
Retrieved lymph nodes (>45) 0.846 (0.634–1.13) 0.258 - -
Tumor size (cm) (>5) 1.864 (1.39–2.5) <0.001* 1.376 (0.983–1.928) 0.063
Differentiation (P/S vs. W/M) 1.076 (0.781–1.481) 0.655 - -
Differentiation (O vs. W/M) 1.050 (0.573–1.923) 0.876 - -
Lauren classification (D vs. I) 1.053 (0.759–1.461) 0.755 - -
Lauren classification (M vs. I) 1.064 (0.634–1.787) 0.814 - -
Lymphatic invasion 1.598 (1.11–2.299) 0.012* 0.907 (0.589–1.396) 0.657
Vascular invasion 1.698 (1.257–2.292) 0.001* 1.222 (0.867–1.723) 0.252
Incompletion of planned chemotherapy 2.552 (1.913–3.406) <0.001* 2.213 (1.618–3.028) <0.001*
HR = hazard ratio; CI = confidence interval; ASA = American society of anesthesiologist; BMI = body mass index; Differentiation: W = well-differentiated; M = 
moderately-differentiated; P = poorly-differentiated; S = signet ring cell carcinoma; O = others; Lauren classification: D = diffuse; I = intestinal; M = mixed.
*Statistically significant with P<0.05.
monotherapy in terms of efficacy on DFS [3]. This survival discrepancy might be due to the 
different AJCC stages, 7th or 8th, and the slight differences in planned AC completion rates 
between the past and present studies. A previous retrospective multicenter study investigated 
actual patient compliance to AC [9]. In line with this study, the actual completion rates of S-1 
and CAPOX were 65.9% and 70.3%, respectively. In a retrospective multicenter observational 
study [3], the completion rates of planned AC were 79.76% and 76.37% in the S-1 and 
CAPOX groups, respectively, after PSM. We also performed PSM to reduce bias due to the 
retrospective nature of data collection, and observed planned AC completion rates of 68.53% 
in the S-1 group and 69.03% in the CAPOX group. Another potential cause of discrepancies 
in survival might be the somewhat small numbers of patients in the CAPOX group (43, 32, 
and 28 patients with stage IIIA, IIIB, and stage IIIC GC, respectively), compared with those in 
the S-1 group (106, 94, and 85 patients with stage IIIA, IIIB, and stage IIIC GC, respectively). 
In the present study, the HRs for GC recurrence of S-1 compared with those of CAPOX 
were below 1 in the subgroups of patients with stage III GC, at 0.873 (95% CI, 0.466–1.635; 
P=0.671) for stage IIIA, and 0.813 (95% CI, 0.482–1.371; P=0.437) for stage IIIC, although 
the HRs did not reach statistical significance. Additional large-scale, prospective studies are 
needed to confirm these differences in survival.
Recent studies have reported the use of other AC regimens, such as S-1 with oxaliplatin 
and taxane. The RESCUE-GC study aimed to elucidate the efficacy of S-1 alone compared 
with that of S-1 plus oxaliplatin for AC in patients with locally advanced GC after curative 
gastrectomy [10]. The JACCRO GC-07 study is a prospective randomized phase III study that 
aimed to assess the effect of postoperative S-1 plus docetaxel over S-1 alone in patients with 
stage III GC [11]. The analysis clarified the superiority of S-1 plus docetaxel (66%) over S-1 
(50%) in terms of 3-year DFS with manageable adverse effects. AC regimens are expected 
to become more diverse. The differences in survival and adverse effects between these AC 
regimens require direct comparisons to determine the best choice of regimen. Two phase 
II studies, the J-CLASSIC and SOXaGC trials, analyzed the patient compliance and safety 
of CAPOX and S-1 plus oxaliplatin regimens [12,13], but they did not investigate oncologic 
outcomes as the primary end points. However, in another 2 phase II study, the observational 
study cohort was designed with somewhat small size of enrolled patients to analyze survival 
outcomes [14]. This ad hoc cohort study revealed that CAPOX and S-1 plus oxaliplatin 
regimens in the adjuvant setting have similar oncologic efficacy for patients with pathologic 
stage III GC. The findings of previous studies showed that doublet AC regimens might have 
comparable efficacies, whereas monotherapies tended to have inferior capability to suppress 
recurrence compared with doublet regimens [3,8]. To the best of our knowledge, the current 
propensity score-matched multicenter cohort study was the first report comparing long-term 
DFS outcomes between a monotherapy and a doublet regimen as an AC.
Our findings showed similar long-term oncologic outcomes despite the different regimens, 
indicating the need to consider factors other than chemotherapeutic regimens that may 
affect patient prognosis. For example, the duration of chemotherapy may explain the 
differences in 3- and 5-year oncologic outcomes of patients with GC [3]. Moreover, the 
long-term outcomes of GC patients might also be affected by factors related to GC (e.g., 
histologic classification, lymphatic or venous invasion, and c-erbB2 status).
Therefore, a nomogram should be established to extend the duration of AC according to 
the disease categories. On the basis of these factors, physicians may administer additional 
chemotherapeutic agents after the currently accepted AC in cases of highly aggressive GC. 
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Additional strategies are needed to enhance compliance to complete AC in patients with 
intractable AGC. 
In conclusion, although the present study was limited by its retrospective design, the PSM 
analysis in this multicenter cohort study clarified that the AC regimens S-1 and CAPOX did 
not show significant difference in terms of over-5yr DFS after curative gastrectomy in patients 
with stage II or III GC.
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